Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.74 |
| ▸ | FBP1 | P09467 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27633480 | 0.89 | ADORA2A (0.74) | ADORA2AFBP1KDM4EPTPN1GAA | |
| SCHEMBL1166869 | 0.88 | ADORA2A (0.59) | ADORA2AFBP1KDM4EPTPN1GSK3B | |
| SCHEMBL13312245 | 0.85 | ADORA2A (0.70) | ADORA2AFBP1KDM4EPTPN1GAA | |
| SCHEMBL3285917 | 0.85 | ADORA2A (1.00) | ADORA2AFBP1KDM4EPTPN1GAA | |
| SCHEMBL2819322 | 0.85 | ADORA2A (0.56) | ADORA2AFBP1KDM4EGAAGSK3B | |
| SCHEMBL631985 | 0.85 | ADORA2A (0.70) | ADORA2AFBP1KDM4EPTPN1GAA | |
| SCHEMBL1167030 | 0.84 | ADORA2A (0.54) | ADORA2AFBP1KDM4EGAAGSK3B | |
| SCHEMBL1166663 | 0.84 | KMT2A (0.56) | ADORA2AFBP1KDM4EGAAGSK3B | |
| SCHEMBL20376680 | 0.84 | ADORA2A (0.54) | ADORA2AFBP1KDM4EPTPN1GAA | |
| SCHEMBL3758327 | 0.84 | ADORA2A (0.54) | ADORA2AFBP1KDM4EPTPN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2648724-B1 | HYDROXYLATED AMINOTRIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-09-21 | — | — | EP | claimed |
| US-9346793-B2 | Hydroxylated aminotriazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS, LTD. (CH) | 2016-05-24 | — | — | US | claimed |
| EP-2440555-B1 | FLUORINATED AMINOTRIAZOLE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2016-05-18 | — | — | EP | claimed |
| US-9303023-B2 | Pyrazole and imidazole derivatives useful as orexin antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-04-05 | — | — | US | claimed |
| EP-2675801-B1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-04-08 | — | — | EP | claimed |
| CN-102803237-B | Oxazole and thiazole derivatives as alx receptor agonists | ACTELION PHARMACEUTICALS LTD | 2014-09-24 | — | — | CN | claimed |
| EP-1742925-B1 | SUBSTITUTED 5, 6, 7, 8-TETRAHYDRO-PYRIDO[4, 3-D]PYRIMIDINE-2-YL COMPOUNDS AND 5, 6, 7, 8-TETRAHYDRO-QUINAZOLINE-2-YL COMPOUNDS | GRUENENTHAL GMBH (DE) | 2014-04-23 | — | — | EP | claimed |
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | claimed |
| CN-101903378-B | Aminotriazole derivatives | ACTELION PHARMACEUTICALS LTD | 2014-03-12 | — | — | CN | claimed |
| EP-2675801-A1 | NOVEL PYRAZOLE AND IMIDAZOLE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-12-25 | — | — | EP | claimed |
| WO-2005089770-A1 | BENZODIAZEPINES FOR TREATING OR PREVENTING OR PREVENTING RSV INFECTION | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089771-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND A INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| EP-1333824-B1 | TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | claimed |
| CN-1518445-A | Treatment of sexual dysfunction | 沃纳-兰伯特公司 | 2004-08-04 | — | — | CN | claimed |
| US-20040116440-A1 | Bombesin receptor antagonists | WARNER-LAMBERT COMPANY LLC | 2004-06-17 | — | — | US | claimed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | claimed |
| EP-1334100-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-13 | — | — | EP | claimed |
| US-20020169101-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY | 2002-11-14 | — | — | US | claimed |
| WO-2002040469-A1 | BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | ADORA2A 2261/4885FBP1 277/4885KDM4E 3348/4885 |
| US-20020169101-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | ADORA2A 2261/4885FBP1 277/4885KDM4E 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.